Nasus Pharma (NSRX) Common Equity (2024 - 2025)
Nasus Pharma (NSRX) reported Common Equity of $2.8 million for Q4 2025, up 186.18% on a YoY basis from $967234.1 in Q4 2024, and up 186.18% quarter-over-quarter from -$3.2 million in Q4 2024.
Nasus Pharma (NSRX) Common Equity (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Common Equity for 2 years, with the latest figure at $2.8 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 186.18% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (up 186.18% YoY), and the FY2025 full-year result was $2.8 million, up 186.18% from the prior year.
- Common Equity for Q4 2025 stood at $2.8 million, up from -$3.2 million in the prior quarter.
- The five-year high for Common Equity was $2.8 million in Q4 2025, with the low at -$3.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 23.49 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 31.20 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 81.19 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -6.61 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 45.93 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 9.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 23.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 90.40 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 20.10 Bn |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | 2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | -3.21 Mn |